Inscripta® closes $150M VC round, scores first commercial buyer of CRISPR gene editing platform
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses.
Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses.